

Development of peptide-based personal cancer vaccine NEO-PV-01

Jesse Z. Dong

VP, Peptide Chemistry at BioNTech US
jessezdong@hotmail.com

Immune and clinical data on the personal neoantigen-based cancer vaccine NEO-PV-01 in combination with anti-PD1 in Phase 1b trial will be presented. The GMP manufacturing process for NEO-PV-01 will also be discussed.